Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Brea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.
Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Adrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.
In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
The use of bispecific antibodies has the potential to revolutionize the management of FL.
Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.
Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.
Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.
Lindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.
Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.